When synthesised with preclinical and mechanistic studies, the findings from this systematic review support the repurposing of PDE5 inhibitors as immunomodulatory agents, particularly in populations with cardiometabolic disease, systemic inflammation, or endothelial dysfunction [13,47]. The gene discussed is PDE5A; the disease is endothelial dysfunction.